How in-home clinical care services generate real-world evidence that supports market access

When we talk about evidence in healthcare, we often picture clinical trials, controlled variables and outcomes captured at fixed points in time. However, much of what truly matters happens elsewhere – in ordinary homes, between doses and in the rhythm of daily life. Home is where people manage symptoms, adapt routines and make the real decisions that can dramatically impact on health outcomes.

Sciensus has been involved in a research programme designed to bring that everyday reality into clearer view. The study focused on UK patients receiving complex, specialist treatment at home and set out to understand how the therapy is used in practice, how people respond to it over long periods and when additional support is needed. As a result, three analyses have now been presented at the 2025 British Society for Immunology Clinical Immunology Professional Network (BSI-CIPN) annual conference, offering one of the most detailed sets of home-based, real-world clinical insight in this particular-therapy area to date.

A window into lived experience, beyond clinical outcomes

The research followed more than 80 adults over a 12-month period, with data gathered prospectively through Sciensus in-home clinical care services. Rather than relying solely on medical notes or retrospective conversations, patients self-reported events regularly, tracking fluctuations, response to medication, episodes requiring action and changes in wellbeing. In simple terms, life was transformed into a rigorous scientific dataset.

Longitudinal, home-based reporting gives us sight of what happens between clinic visits – the decisions and patterns that shape real health outcomes. This level of scientific detail and valuable patient voice rarely appears in traditional datasets, but it’s vital for planning future research and access strategies.

That granularity highlighted several themes:

• Treatment routines varied widely between individuals
• Preventive approaches led to different patterns of breakthrough events
• Some patients experienced long stretches of stability; others reported episodes that escalated quickly, requiring rapid intervention
• Emergency attendance data also helped contextualise severity and burden
• Real life patient experience didn’t match the algorithms of the national guidelines

Why this matters for research and decision-making

Real-world evidence (RWE) offers something healthcare systems increasingly need: context. It adds texture to the clinical picture by capturing lifestyle, comorbidities, confidence and routine information; all of which can support pragmatic improvements to national guidelines. It also highlights where patients may still need support, including education, dose management or emotional counselling.

For patients, these insights ensure their voices become part of the evidence base, not an afterthought. For health system clinicians, the insights offer visibility into what patients experience outside the clinic. For industry, the insights support better-designed studies, more accurate burden estimation and stronger health-economic cases

A step towards more human evidence

This work does not replace trials. However, as the patient voice is given more weight in regulatory and HTA reimbursement decisions, this study demonstrates how working with a non-traditional study partner using an integrated in-home clinical care model can generate meaningful data that would be extremely difficult to collect at scale without regular touchpoints, structured logging and clinical continuity. Traditional evidence tells us if a treatment works. Real-world evidence helps us understand how it works in everyday life, for whom and provides insights into how to create future medicines.

Our direct engagement with over 300,000 patients annually puts Sciensus in a unique position to provide rigorous data capture via advanced digital tools and deliver robust real-world data sourced from early access programmes (EAP), non-interventional studies, post-authorisation studies (PASS) and patient support programmes (PSP). As healthcare moves toward more personalised, insight-driven decision-making, Sciensus remains committed to enabling studies – across the entire drug development life cycle – that reflect the nuance of lived experience for patients.